🎙️ Just published a new episode of Blood Podcast: Review Series on Clonal Tracking in Hematopoiesis. Have a listen:
Sepsis-triggered proteolysis of A2 reduces cell surface fibrinolytic activity. A2 proteolysis is associated with microvasculopathic organ dysfunction in humans. Read in Blood VTH: ow.ly/BmOL50Z5cx8
🎙️ Just published a new episode of Blood Podcast: Future Directions in Relapsed and Refractory Large B-cell Lymphoma. Have a listen:
New issue of Blood out now featuring Ven-aza and the bone marrow niche, Complement activation in ITP, CD7 CAR T cells for relapsed/refractory AML, and more. Explore here: ashpublications.org/blood/issue/...
New issue of Blood Global Hematology out now! Featuring Developing nations’ guide to Hodgkin lymphoma, The challenge of treating African children with hydroxyurea, Sickle cell disease: then and now, and more. Explore here: ashpublications.org/bloodglobal/...
New issue of Blood out now featuring Predictive markers of glofitamab resistance, CREBBP mutations and lymphomagensis, Arterial thrombosis in hypofibrinogenemia and more. Explore here: ashpublications.org/blood/issue/...
New issue of Blood Advances out now featuring Real-world experience with tabelecleucel, Management of relapsed/refractory AL amyloidosis, and more. Explore here: ashpublications.org/bloodadvance...
In this Review series episode, Blood associate editor Dr. Diane Krause...
A real-world cohort of patients with secondary #erythrocytosis had higher rates of #thrombosis compared with treated PV. Secondary erythrocytosis was associated with a higher prevalence of smoking, obesity, and diabetes mellitus. Read in Blood RCI: ow.ly/qBZZ50Z5bV7
Congratulations to our Deputy Editor of Blood, Dr. Jorge Di Paola, on his new role as Executive Vice President and Chief Scientific Officer at @versitiresearch.bsky.social starting in October! Learn more: versiti.org/stories-and-...
In this week's episode, Blood editor Dr. Philippe Armand interviews Drs....
Nationally recognized physician-scientist and longtime collaborator joins Versiti executive leadership team to guide the next phase of blood health research and innovation
I’m excited to share that my PhD paper is officially out now in @bloodjournals.hematology.org
Check out our discovery of how mutant IDH1 but not IDH2 leads to a lineage-specific differentiation block via epigenetic repression of lineage programs!
📄 Paper link below: 👇
doi.org/10.1182/bloo...
🧵 NEW PAPER in @bloodjournal.bsky.social!
Why do IDH1 mutations almost exclusively drive myeloid #leukemia, while IDH2 mutations occur in both myeloid AND lymphoid cancers? 🤔 #AML #Epigenetics
Despite sharing the same biochemical mechanism, they are NOT equivalent. Here's what we found 👇
